

**CRYSTALLINE (8*S*,9*R*)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1*H*-1,2,4-
TRIAZOL-5-YL)-8,9-DIHYDRO-2*H*-PYRIDO[4,3,2-*DE*]PHTHALAZIN-3(7*H*)-ONE
TOSYLATE SALT**

5

Abstract

Provided herein are (8*S*, 9*R*)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1*H*-1,2,4-triazol-5-yl)-8,9-dihydro-2*H*pyrido[4,3,2-*de*]phthalazin-3(7*H*)-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a
10 (8*S*,9*R*)-5-fiuoro-8-(4-fluorophenyl)-9-(1-methyl-1*H*-1,2,4-triazol-5-yl)-8,9-dihydro-2*H*-pyrido[4,3,2-*de*]phthalazin-3(7*H*)-one tosylate salt are also provided, as are methods of using (8*S*,9*R*)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1*H*-1,2,4-triazol-5-yl)-8,9-dihydro-2*H*-pyrido[4,3,2-*de*]phthalazin-3(7*H*)-one tosylate salt to treat a disease or condition, such as a cancer.

15

No suitable figure